SWOG clinical trial number
SWOG-8949

A Randomized Comparison of Nephrectomy Followed by Interferon Alpha 2-b (Intron-A) vs. Interferon Alpha 2-b (Intron-A) Alone in Patients with Advanced Renal Cell Carcinoma

Closed
Phase
III
Accrual
100%
Published
Abbreviated Title
Renal
Activated
03/01/1991
Closed
10/01/1998

Research committees

Genitourinary Cancer

Treatment

Surgery Interferon alpha-2b

Publication Information Expand/Collapse

2020

Association of Patient Demographic Characteristics and Insurance Status with Survival in Cancer Randomized Clinical Trials with Positive Findings

JM Unger;CD Blanke;M Leblanc;W Barlow;R Vaidya;M Fleury;SD Ramsey;DL Hershman JAMA Network Open Apr 1;3(4):e203842

PMid: PMID32352530 | PMC number: PMC7193331

2019

Mechanisms and Funding Opportunities in Genitourinary Cancer Clinical Research [Review]

C Ryan Urologic Oncology: Seminars and Original Investigations, May;37(5):318-323; Jul 31 [Epub ahead of print]

PMid: PMID30072304

Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma

HL Kim;E Mayerson;E Messing;C Tangen;B Shuch;U Vaishampayan European Urology Focus Nov;5(6):927-929; May 15 [Epub ahead of print]

PMid: PMID31103605 | PMC number: PMC6858992

2018

Value of Anti-Cancer Drugs in SWOG Phase III Clinical Trials: Evidence from Multiple Evaluation Mechanisms

V Nghiem;R Vaidya;M Banegas;D Hershman;J Unger AcademyHealth Annual Research Meeting (June 23-26, 2018, Seattle, WA), poster #B-335

2017

Association between body mass index and cancer survival in a pooled analysis of 22 clinical trials

H Greenlee;J Unger;M Leblanc;S Ramsey;D Hershman Cancer Epidemiology Biomarkers & Prevention 2017 Jan;26(1):21-29; 2016 Dec 16. [Epub ahead of print]

PMid: PMID27986655 | PMC number: PMC5370550

The effect of positive SWOG treatment trials on survival of patients with cancer in the US population

JM Unger;M Leblanc;CD Blanke JAMA Oncology Oct 1;3(10):1345-1351

PMid: PMID28586789; PMC5710507

The impact of positive SWOG treatment trials on population survival

J Unger;M LeBlanc;C Blanke J Clin Oncol 35, 2017 (suppl; abstr 6513); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion

2014

Comparison of survival outcomes among cancer patients treated in and out of clinical trials

J Unger;W Barlow;DP Martin;S Ramsey;M Leblanc;R Etzioni;D Hershman Journal of the National Cancer Institute 106(3):dju002; 2014 Mar 13 [Epub ahead of print];

PMid: PMID24627276 | PMC number: PMC3982777

Association between BMI at treatment initiation and cancer survival across multiple SWOG trials

H Greenlee;J Unger;M Leblanc;D Hershman AACR Research International Conference on Frontiers on Cancer Research Prevention (Sept 28-Oct 1, 2014, New Orleans, LA; poster

2009

Predictors of survival in advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949 [PMID19100570; PMC3394523]

PN Lara;CM Tangen;S Conlon;RC Flanigan;ED Crawford Journal of Urology 181(2):512-516

2008

Predictors of survival in advanced renal cell carcinoma (RCC): long-term results from Southwest Oncology Group trial S8949

S Conlon;CM Tangen;RC Flanigan;ED Crawford Journal of Clinical Oncology 26(15S):260s, #5042

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

Predictors of survival in advanced renal cell carcinoma (RCC): long-term results from Southwest Oncology Group Trial S8949

S Conlon;C Tangen;RC Flanigan;ED Crawford;PN Lara American Society of Clinical Oncology Genitourinary Cancers Symposium, abst. 347

2004

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

RC Flanigan;G Mickisch;R Sylvester;C Tangen;H Van Poppel;ED Crawford Journal of Urology 171:1071-1076

2002

The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy

RA Gatenby;ET Gawlinski;CM Tangen;RC Flanigan;ED Crawford Cancer Research 62:5218-5222

2001

Nephrectomy followed by interferon alfa 2-b compared with interferon alfa-2b alone for metastatic renal-cell cancer

RC Flanigan;SE Salmon;BA Blumenstein;SI Bearman;V Roy;PC McGrath;JR Caton, Jr;N Munshi;ED Crawford New England Journal of Medicine 345(23):1655-1659

2000

Cytoreduction nephrectomy in metastatic renal cancer: the results of Southwest Oncology Group trial 8949

RC Flanigan;BA Blumenstein;S Salmon;SI Bearman;V Roy;SP Balcerzak;PC McGrath;JR Caton;B Barlogie;ED Crawford Journal of Urology 163(4)Suppl:154

Cytoreduction nephrectomy in metastatic renal cancer: the results of Southwest Oncology Group trial 8949

RC Flanigan;BA Blumenstein;S Salmon;ED Crawford Proc of the American Society of Clinical Oncology 19:2a(#3)

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/NRG-GU005
SWOG Clinical Trial Number
S1806

Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer.

Research Committee(s)
Genitourinary Cancer
Activated
04/19/2019
Accrual
24%
Open
Phase
III
SWOG Clinical Trial Number
S1802